New Cancer Framework Ties Epigenetics, DNA Repair and Immunity Into One Immunogenicity Score

Immunotherapy has reshaped modern oncology, but it still fails a large share of the patients who receive it. Two people with similar tumors, similar PD-L1 expression and similar immune-cell infiltration can respond in radically different ways to the same checkpoint-blocking drug, and the field has struggled to explain why. A new hypothesis-and-theory article published in Frontiers in Genetics argues that the problem lies not in the immune biomarkers themselves but in the fragmented way scientists have studied tumor immunogenicity, treating chromatin regulation, DNA repair and immune activation as parallel and largely independent stories rather than as one coupled regulatory system.

The paper, authored by Manyata Srivastava, Shishir Singh, Diksha Ameta, Aesha Singh, Monisha Banerjee and Atar Singh Kushwah, proposes what the team calls the Immunogenicity Control Axis, or ICA. The central idea is deceptively simple: a tumor’s visibility to the immune system is an emergent property that arises only when three molecular layers are coordinated. Epigenetic regulation determines whether immune-relevant genes can be transcribed at all, DNA damage response pathways shape the mutational substrate from which neoantigens are generated, and the immune axis reflects the downstream cytolytic and interferon-driven state that results. Break the chain at any layer, the framework predicts, and even an antigen-laden tumor can remain immunologically invisible.

The epigenetic layer is the framework’s upstream boundary condition. Histone deacetylases and DNA methyltransferases control chromatin accessibility at promoters and enhancers governing MHC class I and II antigen presentation and interferon-responsive signaling. A repressive chromatin state can silence these programs entirely, which means a tumor may harbor abundant immunogenic mutations yet never display the resulting peptides to cytotoxic T cells. The authors point to converging evidence, including studies showing that epigenetic therapy can reverse immune evasion in lung cancer, that chromatin accessibility precedes transcriptional activation of immune genes, making it a plausible causal starting point rather than a mere correlate.

The DNA damage response axis supplies the raw material. Double-strand breaks can be repaired through homologous recombination, classical non-homologous end joining or alternative end joining, and the balance among these pathways differs in fidelity and genomic consequence. The team hypothesizes that repair-pathway configuration contributes to variation in the genomic substrate available for immune recognition, with error-prone end-joining potentially generating distinct spectra of candidate neoantigens. Crucially, the authors are careful not to overclaim: they treat relationships between expression-defined repair states and mutational signatures such as SBS3, linked to homologous-recombination deficiency, and the APOBEC-associated SBS2 and SBS13 signatures, prominent in cervical cancer, as exploratory associations rather than evidence that a specific repair pathway directly forges any particular immunogenic phenotype.

What elevates the paper above a purely conceptual essay is its insistence on quantitative falsifiability. Each axis is operationalized as a standardized score derived from single-sample gene-set enrichment analysis of prespecified transcriptional programs: permissive chromatin and antigen-presentation features contribute positively to the Epigenetic score, the DDR score captures the relative transcriptional shift toward end-joining versus homologous-recombination programs, and the Immune score aggregates cytolytic activity, checkpoint expression and interferon signatures. The composite ICA Score is then computed as the arithmetic mean of the three standardized components, an equal-weight formulation the authors describe deliberately as a transparent, outcome-independent reference model rather than a claim that the three biological systems contribute equally.

Cervical cancer serves as the initial testing ground, and for good reason. HPV-driven tumors coexist with viral antigens that should provoke immune recognition, yet many remain immunologically cold, a paradox the ICA framework attributes to upstream constraints: epigenetic repression can mute antigen presentation despite antigen availability, while repair-pathway bias may yield suboptimal mutation profiles. Using 304 evaluable TCGA-CESC cases, the team dichotomized patients by median ICA Score and found no statistically significant difference in overall survival between high- and low-scoring groups, a negative result they report transparently as exploratory benchmarking rather than validation. In a separate three-year survival classification analysis, however, the ICA composite model achieved an internally cross-validated AUC of 0.931, outperforming TMB plus PD-L1 (0.890), TMB alone (0.869) and PD-L1 alone (0.823), although the authors stress these figures represent in-cohort cross-validation, not independent clinical validation.

The framework extends into a perturbational layer that will likely attract the most attention. Differential-expression analysis between ICA-high and ICA-low tumors generates a bidirectional query signature, which the team matched against compound-induced transcriptional profiles in the LINCS L1000 Connectivity Map resource. Natural compounds whose signatures transcriptionally oppose the ICA-associated state, and whose curated targets span multiple ICA dimensions, are ranked as candidate multi-axis perturbators. Compounds such as curcumin and resveratrol, previously associated with modulation of DNMT and HDAC activity, exemplify the class of agents the framework is designed to evaluate, since their multi-target profiles may in principle touch the epigenetic, DDR and immune layers simultaneously rather than acting on a single isolated node.

The authors are unusually explicit about the epistemic status of every component. Consensus clustering of ICA features, UMAP visualizations of molecular states and even a synthetic demonstration matrix of 30 genes across 80 simulated profiles are all labeled as computational proof of principle, not evidence of biological subtypes. Network connectivity between a compound and an ICA protein is prioritization evidence, not target engagement. The roadmap to validation is staged: molecular reproducibility in independent multi-omics cohorts first, systems-level interrogation of inter-axis relationships second, and clinical benchmarking against PD-L1, TMB and clinicopathological variables in treatment-annotated cohorts only at the final stage, with failure at any step triggering refinement rather than reinterpretation.

The limitations are real. The ICA Score’s component axes are transcriptional and methylation-based correlates, not direct measurements of chromatin accessibility, repair-pathway flux or immune-cell function, and bulk transcriptomic deconvolution methods such as EPIC, xCell and MCP-counter infer rather than measure immune infiltration. The framework’s relative weights may need recalibration across tumor types; in low-mutational-burden cancers, mutation-derived antigenicity may matter less, while hematologic malignancies may require fundamentally different formulations. Prospective validation in independent clinical cohorts, particularly those with documented immunotherapy exposure and response endpoints, remains the decisive test.

Still, the conceptual contribution is difficult to dismiss. By proposing that tumor immunogenicity follows a Regulatory Convergence Principle, in which epigenetic accessibility, repair-pathway bias and immune signaling must align for effective immune visibility, the ICA framework reframes immunotherapy resistance as a systems-level regulatory problem rather than a failure of any single biomarker. It offers the field something it badly needs: a falsifiable, computationally tractable model that connects biological hypothesis to quantitative evaluation, and that specifies in advance what evidence would support or refute it. Whether coordinated multi-axis information truly captures what PD-L1 and tumor mutational burden miss, the coming validation cohorts will tell.

Subject of Research: A multi-omics framework integrating epigenetic regulation, DNA damage response and immune state to explain tumor immunogenicity and immunotherapy response variation

Article Title: The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer

Article References: The immunogenicity control axis: a multi-omics framework for integrating epigenetic, DNA damage response, and immune states in cancer. (n.d.). https://doi.org/10.3389/fgene.2026.1944709

Image Credits: AI Generated

DOI: 10.3389/fgene.2026.1944709

Keywords: immunogenicity control axis, tumor immunogenicity, multi-omics, epigenetics, DNA damage response, immune checkpoint blockade, cervical cancer, TCGA, neoantigens, natural compounds, biomarkers, immunotherapy resistance